Efficacy of Panobinostat for the Treatment of Multiple Myeloma

Overview

Journal J Oncol

Specialty Oncology

Date 2020 May 16

PMID 32411240

Citations 35

Authors

Evangelos Eleutherakis-Papaiakovou

Nikolaos Kanellias

Efstathios Kastritis

Maria Gavriatopoulou

Evangelos Terpos

Meletios Athanasios Dimopoulos

Affiliations

Soon will be listed here.

Abstract

Panobinostat represents a potent oral nonselective pan-histone deacetylase inhibitor (HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in combination with bortezomib and dexamethasone for the treatment of multiple myeloma, in patients who have received at least two prior regimens, including bortezomib and an immunomodulatory agent. In order to further explore its clinical potential, it is evaluated in different combinations in relapsed/refractory and newly diagnosed multiple myeloma. This review focuses on available data about panobinostat's pharmacology and its role in clinical practice. This review will reveal panobinostat's efficacy as antimyeloma treatment, describing drug evolution from preclinical experimental administration to administration in phase III trials, which established its role in current clinical practice. Based on the latest data, we will present its mechanism of action, its efficacy, and most important issues regarding its toxicity profile. We will further try to shed light on its role in current and future therapeutic landscape of myeloma patients. Panobinostat retains its role in therapy of multiple myeloma because of its manageable toxicity profile and its efficacy, mainly in heavily pretreated multiple myeloma patients. These characteristics make it valuable also for novel regimens in combination with second-generation proteasome inhibitors, IMiDs, and monoclonal antibodies. Results of ongoing trials are expected to shed light on drug introduction in different therapeutic combinations or even at an earlier level of disease course.

Citing Articles

Role of Protein Lysine Acetylation in the Pathogenesis and Treatment of Obesity and Metabolic Syndrome.

Li Z, Song Y, Li Z, Liu S, Yi S, Zhang Z Curr Obes Rep. 2025; 14(1):24.

PMID: 40075037 PMC: 11903573. DOI: 10.1007/s13679-025-00615-1.

Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1.

Noguchi R, Ono T, Osaki J, Adachi Y, Iwata S, Shiota Y Hum Cell. 2024; 38(1):28.

PMID: 39645627 DOI: 10.1007/s13577-024-01152-0.

Panobinostat Attenuates Experimental Autoimmune Encephalomyelitis in Mice via Suppressing Oxidative Stress-Related Neuroinflammation and Mitochondrial Dysfunction.

Shen Y, Zhao J, Yang R, Yang H, Guo M, Ji B Int J Mol Sci. 2024; 25(22).

PMID: 39596104 PMC: 11594185. DOI: 10.3390/ijms252212035.

Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells.

Smith K, Trovillion E, Sholler C, Gandra D, McKinney K, Mulama D Cancers (Basel). 2024; 16(21).

PMID: 39518006 PMC: 11545275. DOI: 10.3390/cancers16213565.

Rediscovering hemostasis abnormalities in multiple myeloma: The new era.

Huang Y, Wang C, Wang H, Liu H, Zhou L Heliyon. 2024; 10(13):e34111.

PMID: 39055831 PMC: 11269926. DOI: 10.1016/j.heliyon.2024.e34111.

References

Ropero S, Esteller M . The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2009; 1(1):19-25. PMC: 5543853. DOI: 10.1016/j.molonc.2007.01.001. View

Zou Y, Ma X, Yu H, Hu C, Fan L, Ran X . Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials. Oncotarget. 2016; 8(24):39805-39817. PMC: 5503655. DOI: 10.18632/oncotarget.10768. View

Kumar S, Lee J, Lahuerta J, MORGAN G, Richardson P, Crowley J . Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2011; 26(1):149-57. PMC: 4109061. DOI: 10.1038/leu.2011.196. View

Rajan A, Buadi F, Rajkumar V . Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations. Am J Hematol. 2015; 91(2):E5-6. PMC: 4724346. DOI: 10.1002/ajh.24244. View

Jakubowiak A, Offidani M, Pegourie B, Rubia J, Garderet L, Laribi K . Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016; 127(23):2833-40. PMC: 4900953. DOI: 10.1182/blood-2016-01-694604. View

Richardson P, Schlossman R, Alsina M, Weber D, Coutre S, Gasparetto C . PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013; 122(14):2331-7. DOI: 10.1182/blood-2013-01-481325. View

Lee D, HAYES J, Pruss D, Wolffe A . A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell. 1993; 72(1):73-84. DOI: 10.1016/0092-8674(93)90051-q. View

Mateos M, Dimopoulos M, Cavo M, Suzuki K, Jakubowiak A, Knop S . Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2017; 378(6):518-528. DOI: 10.1056/NEJMoa1714678. View

Attal M, Harousseau J, Stoppa A, Sotto J, Fuzibet J, Rossi J . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996; 335(2):91-7. DOI: 10.1056/NEJM199607113350204. View

10.

Hajek R, Masszi T, Petrucci M, Palumbo A, Rosinol L, Nagler A . A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2016; 31(1):107-114. PMC: 5220126. DOI: 10.1038/leu.2016.176. View

11.

Ray A, Das D, Song Y, Hideshima T, Tai Y, Chauhan D . Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma. Leukemia. 2017; 32(3):843-846. PMC: 5842120. DOI: 10.1038/leu.2017.322. View

12.

Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F . A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006; 12(15):4628-35. DOI: 10.1158/1078-0432.CCR-06-0511. View

13.

DeAngelo D, Spencer A, Bhalla K, Prince H, Fischer T, Kindler T . Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013; 27(8):1628-36. DOI: 10.1038/leu.2013.38. View

14.

Iida S, Watanabe T, Matsumoto M, Suzuki K, Sunami K, Ishida T . Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study. Cancer Sci. 2019; 110(9):2924-2932. PMC: 6726678. DOI: 10.1111/cas.14139. View

15.

Offidani M, Corvatta L, Liberati A, Pulini S, Ballanti S, Bringhen S . Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2017; 59(5):1271-1273. DOI: 10.1080/10428194.2017.1372575. View

16.

Richardson P, Attal M, Campana F, Le-Guennec S, Hui A, Risse M . Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. Future Oncol. 2017; 14(11):1035-1047. DOI: 10.2217/fon-2017-0616. View

17.

Canella A, Nieves H, Sborov D, Cascione L, Radomska H, Smith E . HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget. 2015; 6(31):31134-50. PMC: 4741593. DOI: 10.18632/oncotarget.5290. View

18.

Gao L, Gao M, Yang G, Tao Y, Kong Y, Yang R . Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2. Biomed Res Int. 2015; 2015:459052. PMC: 4427084. DOI: 10.1155/2015/459052. View

19.

Cavenagh J, Popat R . Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat. Clin Lymphoma Myeloma Leuk. 2018; 18(8):501-507. DOI: 10.1016/j.clml.2018.05.007. View

20.

Srinivas N . Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives. Xenobiotica. 2016; 47(4):354-368. DOI: 10.1080/00498254.2016.1184356. View